Logo

Nurix Reports Positive Results of BTK degraders, NX-5948 and NX-2127 in P-Ia/Ib Trial for the Treatment of Lymphoma

Share this
Nurix

Nurix Reports Positive Results of BTK degraders, NX-5948 and NX-2127 in P-Ia/Ib Trial for the Treatment of Lymphoma

Shots:

  • Nurix Therapeutics reveals positive clinical results for its BTK degraders, NX-5948 and NX-2127 in separate P-1a/1b trials for r/r B-cell malignancies. The results of the NX-5948 P-Ia/Ib study depicted dose-dependent PK in cohorts 1-5, (n=26; 50-450 mg) with 4 prior therapies
  • Additionally, CLL patients (50-200 mg) exhibited clinical benefit in 6/7, with ongoing responses; NHL patients (50-450 mg) showed durable responses, & it was well-tolerated across all doses (50-450 mg), with no toxicities or discontinuations by Oct 17, 2023
  • Furthermore, Nurix's NX-2127 trial (Phase Ia/Ib, CLL, MCL, DLBCL) on patients (n=56; aged:50-92; 100-300 mg) showed dose-dependent PK, induced rapid & durable responses, with complete responses in 2/17 NHL patients. In CLL patients, an ORR of 40.7% was observed

Ref: Nurix Image: Nurix

Related News:- Nurix Entered into a Multi-Year, Multi-Target Strategic Collaboration Agreement with Seagen to Advance an Innovative New Class of Cancer Therapies

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Kritika Jha

Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions